Sequana Medical NV

Sequana Medical NV is a Belgium-based medical device innovator specializing in treatments for drug-resistant fluid overload in liver disease, heart failure, and cancer. The company's flagship product, alfapump®, is a fully implantable, wireless active medical device (Class III) that automatically transfers excess abdominal fluid to the bladder for natural elimination via urination. Alfapump® received CE marking in Europe in 2011 and achieved U.S. FDA approval in December 2024 as the first U.S.-approved active implantable device for recurrent or refractory ascites due to liver cirrhosis. Over 1,000 implantations have been performed globally. The POSEIDON pivotal study demonstrated nearly 100% median reduction in therapeutic paracentesis procedures and significant improvements in patient quality of life. Sequana Medical is also developing DSR® (Direct Sodium Removal) therapy for diuretic-resistant heart failure, currently in clinical development. Founded in 2006 and publicly listed on Euronext Brussels since February 2019, the company operates approximately 70 employees and has secured €119.2 million in funding. The organization is committed to advancing clinical evidence through peer-reviewed publications and collaborations with hepatology and cardiology specialists.